MedPath

Methods of Computed Tomography Screening and Management of Lung Cancer

Not Applicable
Conditions
Lung Neoplasms
Computed Tomography
Lung Nodules
Mass Screening
Interventions
Other: lung cancer screening
Registration Number
NCT03992833
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Brief Summary

European lung cancer screening studies using computed tomography (CT) have shown that a management protocol based on measuring lung nodule volume and volume doubling time (VDT) is more specific for early lung cancer detection than a diameter-based protocol. However, whether this also applies to a Chinese population is unclear. The aim of this study is to compare the diagnostic performance of a volume-based protocol with a diameter-based protocol for lung cancer detection and optimize the nodule management criteria for a Chinese population.

Detailed Description

In this population-based study, participants will undergo a low-dose chest CT scan for two rounds. At baseline, the first CT scan will be performed in all participants and their data will be collected. One-year after the baseline, a second CT scan will be performed and data will be collected again. CT images of each participant will be read twice independently by two groups of readers after the baseline and 1-year follow-up scans. In the first reading, the detected lung nodules are evaluated for diameter and managed according to a routine diameter-based protocol. The clinical management of participants are based on the first reading. In the second reading, each scan will be interpreted again by radiologists, blinded to the first reading. Semi-automated volumetry software will be used. The lung nodules will be evaluated for volume and management will be simulated according to a European volume-based protocol. Participants will be followed up and any diagnosis of lung cancer and related information will be collected at the fourth year through the hospital information system and by contacting the participants or their relatives.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
4000
Inclusion Criteria
  • Aged 40-74 years;
  • Resident in the Hexi district of Tianjin city for at least 3 years;
  • Having no self-reported history of any malignant tumor.
Exclusion Criteria
  • Pregnant woman will be excluded.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
lung cancer screeninglung cancer screeningParticipants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules. At baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected.
Primary Outcome Measures
NameTimeMethod
number of clinically diagnosed lung cancerat the fourth year from baseline

The number of clinically diagnosed lung cancer will be collected through the hospital information system and by contacting the participants or their relatives using a questionnaire.

number of lung cancer deathat the fourth year from baseline

The number of lung cancer death will be collected through the hospital information system and by contacting the relatives of the participants using a questionnaire.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Tianjin Medical University Cancer Institute And Hospital

🇨🇳

Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath